Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.2600 (2.24%) ($5.0300 - $5.3200) on Wed. Sep. 2, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.87% (three month average) | RSI | 64 | Latest Price | $5.2600(2.24%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS advances 1.6% a day on average for past five trading days. | Weekly Trend | ADMS advances 3.2% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) BND(30%) TIP(27%) BNDX(22%) BWX(22%) CEMB(22%) | Factors Impacting ADMS price | ADMS will decline at least -3.935% in a week (0% probabilities). PAVE(-21%) XLI(-17%) XLB(-13%) XHB(-13%) XLRE(-12%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -3.935% (StdDev 7.87%) | Hourly BBV | -1.6 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $5.15(2.14%) | 10 Day Moving Average | $4.94(6.48%) | 20 Day Moving Average | $4.74(10.97%) | To recent high | 0% | To recent low | 4.2% | Market Cap | $149m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |